The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis

Brain, Behavior, and Immunity

Volumn 32, Issue , 2013, Pages 180-185

  Golan, Daniel ^a   Staun Ram, Elsebeth ^a   Glass Marmor, Lea ^a   Lavi, Idit ^a   Rozenberg, Orit ^b   Dishon, Sara ^a   Barak, Mira ^b   Ish Shalom, Sophia ^c   Miller, Ariel ^a,c  

^a CARMEL MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Chronotherapy; Interferon ; Light; Melatonin; Multiple sclerosis; Neurohormone; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; CALCIUM; COLECALCIFEROL; MELATONIN;

ADULT; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HORMONE RELEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN SECRETION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION; URINE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WELLBEING; YOUNG ADULT;

EID: 84891371410     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.04.010     Document Type: Article

References (47)

1. Agafonkin, V., 2009. SunCalc: Sunrise and sunset calculator. (last accessed 04.13.).
2. Akpinar, Z., Tokgoz, S., Gokbel, H., Okudan, N., Uguz, F., Yilmaz, G., 2008. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res. 161, 253-257.
3. Ascherio, A., Marrie, R.A., 2012. Vitamin D in MS: a vitamin for 4 seasons. Neurology 17, 208-210.
4. Binkley, N., Gemar, D., Engelke, J., Gangnon, R., Ramamurthy, R., Krueger, D., Drezner, M.K., 2011. Evaluation of ergocalciferol or cholecalciferol dosing, 1600 IU daily or 50,000 IU monthly in older adults. J. Clin. Endocrinol. Metab. 96, 981-988.
5. Bojkowski, C.J., Arendt, J., 1988. Annual changes in 6-sulphatoxymelatonin excretion in man. Acta Endocrinol. 117, 470-476.
6. Bringhurst, F.R., Demay, M., Kronenberg, H.M., 2008. Hormones and disorders of mineral metabolism. In: Kronenberg, H.M., Melmed, S., Polonsky, K.S., Larsen, P.R. (Eds.), Williams Textbook of Endocrinology, eleventh ed. Saunders, Elsevier, Philadelphia, PA, pp. 1217-1218.
7. Brzezinski, A., 1997. Melatonin in humans. N. Engl. J. Med. 336, 186-195.
8. Buxton, I., 2006. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Brunton, L.L., (Ed.), Goodman & Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill Medical Publishing Division, New York, pp. 1-41.
9. Cantorna, M.T., Hayes, C.E., DeLuca, H.F., 1996. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 93, 7861-7864.
10. Cella, D.F., Dineen, K., Arnason, B., Reder, A., Webster, K.A., Karabatsos, G., Chang, C., Lloyd, S., Steward, J., Stefoski, D., 1996. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47, 129-139.
11. Disanto, G., Morahan, J.M., Ramagopalan, S.V., 2012. Multiple sclerosis: risk factors and their interactions. CNS Neurol. Disord. Drug 11, 545-555.
12. Eyles, D.W., Smith, S., Kinobe, R., Hewison, M., McGrath, J.J., 2005. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 29, 21-30.
13. Fernandes de Abreu, D.A., Eyles, D., Feron, F., 2009. Vitamin D, a neuroimmunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 34 (Suppl. 1), S265-S277.
14. Gallagher, J.C., Yalamanchili, V., Smith, L.M., 2012. The effect of vitamin D supplementation on serum 25OHD in thin and obese women. J. Steroid Biochem. Mol. Biol. http://dx.doi.org/10.1016/j.jsbmb.2012.12.003.
15. Garcia-Maurino, S., Gonzalez-Haba, M.G., Calvo, J.R., Rafii-El-Idrissi, M., Sanchez-Margalet, V., Goberna, R., Guerrero, J.M., 1997. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 159, 574-581.
16. Glass-Marmor, L., Paperna, T., Ben-Yosef, Y., Miller, A., 2007. Chronotherapy using corticosteroids for multiple sclerosis relapses. J. Neurol. Neurosurg. Psychiatry 78, 886-888.
17. Glass-Marmor, L., Paperna, T., Galboiz, Y., Miller, A., 2009. Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. J. Neuroimmunol. 210, 124-127.
18. Gonsette, R.E., 2008. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci. 274, 48-53.
19. Harms, L.R., Burne, T.H., Eyles, D.W., McGrath, J.J., 2011. Vitamin D and the brain. Best Pract. Res. Clin. Endocrinol. Metab. 25, 657-669.
20. Hart, P.H., Gorman, S., Finlay-Jones, J.J., 2011. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat. Rev. Immunol. 11, 584-596.
21. Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., Murad, M.H., Weaver, C.M., 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911-1930.
22. Ish-Shalom, S., Segal, E., Salganik, T., Raz, B., Bromberg, I.L., Vieth, R., 2008. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J. Clin. Endocrinol. Metab. 93, 3430-3435.
23. Kennaway, D.J., Royles, P., 1986. Circadian rhythms of 6-sulphatoxy melatonin, cortisol and electrolyte excretion at the summer and winter solstices in normal men and women. Acta Endocrinol. 113, 450-456.
24. Lemire, J.M., Archer, D.C., 1991. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87, 1103-1107.
25. Liu, F., Ng, T.B., Fung, M.C., 2001. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J. Neural. Transm. 108, 397-405.
26. Løken-Amsrud, K.I., Holmøy, T., Bakke, S.R.J., Beiske, A.G., Bjerve, K.S., Bjørnarǎ, B.T., Hovdal, H., Lilleǎs, F., Midgard, R., Pedersen, T., Benth, J.A., Sandvik, L., Torkildsen, Ø., Wergeland, S., Myhr, K.-M., 2012. Vitamin D and disease activity in multiple sclerosis before and during interferonb treatment. Neurology 79, 267-273.
27. Lucas, R.M., Ponsonby, A.L., Dear, K., Valery, P.C., Pender, M.P., Taylor, B.V., Kilpatrick, T.J., Dwyer, T., Coulthard, A., Chapman, C., van der Mei, I., Williams, D., McMichael, A.J., 2011. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76, 540-548.
28. Mehta, B.K., 2010. New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. J. Neurol. Sci. 292, 5-10.
29. Melamud, L., Golan, D., Luboshitzky, R., Lavi, I., Miller, A., 2012. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J. Neurol. Sci. 314, 37-40.
30. Munger, K.L., Levin, L.I., Hollis, B.W., Howard, N.S., Ascherio, A., 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Jama 296, 2832-2838.
31. Pandi-Perumal, S.R., Srinivasan, V., Spence, D.W., Cardinali, D.P., 2007. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 21, 995-1018.
32. Radogna, F., Diederich, M., Ghibelli, L., 2010. Melatonin: a pleiotropic molecule regulating inflammation. Biochem. Pharmacol. 80, 1844-1852.
33. Reiter, R.J., Tan, D.X., Jou, M.J., Korkmaz, A., Manchester, L.C., Paredes, S.D., 2008. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro. Endocrinol. Lett. 29, 391-398.
34. Robertson, N.J., Faulkner, S., Fleiss, B., Bainbridge, A., Andorka, C., Price, D., Powell, E., Lecky-Thompson, L., Thei, L., Chandrasekaran, M., Hristova, M., Cady, E.B., Gressens, P., Golay, X., Raivich, G., 2013. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 136, 90-105.
35. Ruhayel, Y., Malm, G., Haugen, T.B., Henrichsen, T., Bjorsvik, C., Grotmol, T., Saether, T., Malm, J., Figenschau, Y., Rylander, L., Levine, R.J., Giwercman, A., 2007. Seasonal variation in serum concentrations of reproductive hormones and urinary excretion of 6-sulfatoxymelatonin in men living north and south of the Arctic Circle: a longitudinal study. Clin. Endocrinol. 67, 85-92.
36. Saliba, W., Rennert, H.S., Kershenbaum, A., Rennert, G., 2012. Serum 25(OH)D concentrations in sunny Israel. Osteoporos. Int. 23, 687-694.
37. Saliba, W., Barnett-Griness, O., Rennert, G., 2013. The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation. Osteoporos. Int. 24, 1447-1454.
38. Sandyk, R., Awerbuch, G.I., 1992. Nocturnal plasma melatonin and alphamelanocyte stimulating hormone levels during exacerbation of multiple sclerosis. Int. J. Neurosci. 67, 173-186.
39. Sandyk, R., Awerbuch, G.I., 1993. Multiple sclerosis: relationship between seasonal variations of relapse and age of onset. Int. J. Neurosci. 71, 147-157.
40. Sandyk, R., Awerbuch, G.I., 1993b. Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders. Int. J. Neurosci. 68 (3-4), 227-240.
41. Schernhammer, E.S., Kroenke, C.H., Dowsett, M., Folkerd, E., Hankinson, S.E., 2006. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J. Pineal Res. 40, 116-124.
42. Simpson Jr., S., Blizzard, L., Otahal, P., Van der Mei, I., Taylor, B., 2011. Latitude is significantly associated with the prevalence of multiple sclerosis: a metaanalysis. J. Neurol. Neurosurg. Psychiatry 82, 1132-1141.
43. Smolders, J., Damoiseaux, J., Menheere, P., Hupperts, R., 2008. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 194, 7-17.
44. Smolders, J., Thewissen, M., Peelen, E., Menheere, P., Tervaert, J.W., Damoiseaux, J., Hupperts, R., 2009. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 4, e6635.
45. Stewart, N., Simpson, S., van der Mei, I., Ponsonby, A.-L., Blizzard, L., Dwyer, T., Pittas, F., Eyles, D., Ko, P., Taylor, B.V., 2012. Interferon-b and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 79, 254-260.
46. Stokkan, K.A., Reiter, R.J., 1994. Melatonin rhythms in Arctic urban residents. J. Pineal Res. 16, 33-36.
47. Wetterberg, L., Bergiannaki, J.D., Paparrigopoulos, T., von Knorring, L., Eberhard, G., Bratlid, T., Yuwiler, A., 1999. Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 24, 209-226.